Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Last week, the First-in-Human study with 2B3- 201, to-BBB's second product, was initiated at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands. This Phase I trial is designed to determine the safety profile, and will also give a first glance at the pharmacological profile. In this double-blind crossover study, 18 healthy volunteers are assigned to three cohorts in which they will receive an ascending single dose of 2B3-201, as well as placebo and standard of care methylprednisolone.
2B3-201 is being developed for treatment of diseases with neuroinflammation, such as acute relapses of multiple sclerosis (MS). The current standard of care methylprednisolone is effective, yet it requires high dose infusions for several days. This often results in side effects and inconvenience for the patient. Therefore, there is a high medical need for an effective treatment that could be given at lower doses with a more convenient dosing regimen.
"to-BBB's G-Technology® provides a safe method to enhance the slow and sustained delivery of drugs to the brain," says Werner Gladdines, Head of Development at to-BBB. "By combining this technology with methylprednisolone, 2B3-201 was developed and tested in nonclinical models with neuroinflammation, in which it showed a similar efficacy at single administration with a 10 times lower dose compared to multiple high doses of methylprednisolone."
Following an extensive nonclinical development program, to-BBB initiated the Phase I clinical trial. The aim of this First-in-Human study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of 2B3-201 in healthy volunteers, in comparison to placebo and methylprednisolone. Using a double-blind crossover design, each healthy volunteer receives an infusion of 2B3-201, placebo and methylprednisolone with 1-week intervals, thereby acting as his own control.
"Next to the standard safety parameters and pharmacokinetics, assessments of effects on cognition, behavior, and glucose tolerance will be evaluated," adds Dr. Geert Jan Groeneveld, Research Director Neurology & Pain at CHDR. "By including specific neurological tests in CHDR's NeuroCart and therapeutic dose levels of methylprednisolone in the control arm, this study allows for an extensive read-out of pharmacological and neurological effects."
2B3-201 is expected to follow a relatively short route towards marketing authorization. In addition to acute MS relapses, there is significant therapeutic potential in related inflammatory diseases, such as optic neuritis, neuromyelitis optica (NMO), uveitis, Behçet's disease, sarcoidosis, and neuropathic pain.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Multiple Sclerosis category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
to-BBB. "Improved anti-inflammatory therapy for acute MS relapses." Medical News Today. MediLexicon, Intl., 19 Dec. 2013. Web.
7 Mar. 2014. <http://www.medicalnewstoday.com/releases/270363>
to-BBB. (2013, December 19). "Improved anti-inflammatory therapy for acute MS relapses." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/270363.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.